That's actually the case, I think, on both the human side and the veterinary side. Studies may be cheaper in other countries. That could be one of the reasons. But if it has to do with the regulatory approval process, we can be assured that there is an opportunity for these types of studies to come back, especially with some of the strategies that we have put in place in the last couple of years.
On April 1st, 2008. See this statement in context.